Found 392 matching trials
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma PHASE1 This is a phase I, interventional, single-arm, open-label, dose-finding tre...
Show More Location
Froedtert & the Medical College of Wisconsin
Learn More & Join Trial
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL PHASE1 Alloimmune-mediated platelet transfusion refractoriness(PTR) was usually ca...
Show More Location
The First Affiliated Hospital of Soochow University
Learn More & Join Trial
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma PHASE1 The purpose of this clinical trial is to learn if allogeneic cord blood-der...
Show More Location
Xi'an No.3 Hospital
Learn More & Join Trial
T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma PHASE1 This is a single-center, open-label, single-arm study to evaluate the safet...
Show More Location
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease EARLY_PHASE1 A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen R...
Show More Learn More & Join Trial
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma PHASE1 The purpose of the study is to characterize safety of JNJ-68284528 and esta...
Show More Location
Mayo Clinic Cancer Center-Scottsdale
Learn More & Join Trial
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM PHASE1 To explore the safety and efficacy of nanobody-based BCMA-targeting biepito...
Show More Location
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease EARLY_PHASE1 This is an exploratory, open-label, single-arm Phase 1 clinical study desig...
Show More Location
Children's Hospital, Zhejiang University School of Medicine
Learn More & Join Trial
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma EARLY_PHASE1 The goal of this clinical trial is to study the feasibility and efficacy of...
Show More Location
Shanghai Changzheng Hospital
Learn More & Join Trial
CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma PHASE1 This is a single arm, open-label, single-center, phase 1 study, to determin...
Show More Location
Second Affiliated Hospital of Xi'an Jiaotong University
Learn More & Join Trial